Human immunodeficiency virus type 1 (1IV-1) strains were Isolated from nine patients before and after prolonged therapy with either an alternating regimen of 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dldeoxycytldin (ddC) (AZT/ddC) or 2',3'-deoxyinosine (ddl) alone. AN strains obtained from four patients who received AZT/ddC for up to 41 mo were highly insensitive to AZT in vitro. Only one strain obtained after AZT/ddC therapy showed reduced susceptibility to ddC in addition to AZT and had previously unreported amino acid substitutions in the viral polymeraseending pol region, whereas three other strains had one or more of the five previously reported AZT-related mutations. In flve HIV-1 strains from patents who received ddI for up to 29 mo, no appreciable decrease in sensitivity to ddl was detect.
mo, no appreciable decrease in sensitivity to ddl was detect.
Two strains Isolated after ddI therapy had no t amino acid mutations, although three strains had a mutation reportedly acited with ddI administration. These data suggest that HIV-1 develops reduced susceptibility to AZT more readily than to ddC and ddI and/or that the reduced susceptibility to ddC and ddI is modest in degree. Moreover, the present data suggest that an alternating regimen of AZT and ddC does not block the emergence of AZT-ensitve va . It should be noted, however, that the current results do not provide a basds for concluding that AZT/ddC or ddI is inferior, equivalent, or superior to AZT as therapy of AIDS.
The ability to provide effective long-term antiretroviral therapy using single agents for human immunodeficiency virus type 1 (HIV-1) infection became a complex issue when HIV-1 strains that were less susceptible to 3'-azido-3'-deoxythymidine (AZT or zidovudine) in vitro were isolated from patients with AIDS who received long-term AZT therapy (1) (2) (3) . Two 2',3'-dideoxynucleosides, 2',3'-dideoxyinosine (ddN or didanosine) and 2',3'-dideoxycytidine (ddC), have been shown to have clinical activity in patients with HIV-1 infection (4) (5) (6) (7) (8) . St . Clair et al. (9) have recently reported that patients who received long-term AZT therapy and then ddl therapy developed reduced susceptibility to ddI and that the emergence of ddI insensitivity was associated with a reversion to a more AZT-sensitive phenotype. However, the behavior of HIV-1 at the genetic and phenotypic level upon exposure to multiple antiretroviral agents is as yet poorly understood. In the current study, we specifically asked how easily HIV-1 develops reduced sensitivity to three drugs: AZT, ddC, and ddI, when given as single drugs or in combination. We also asked whether the addition of ddC to AZT therapy in an alternating regimen could block the emergence of AZT-insensitive HIV-1 variants.
MATERIALS AND METHODS
Nucleosides. ddC and ddl for in vitro use were provided by the Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, whereas AZT was purchased from Sigma.
of Clinical HIV-1 Strains. HIV-1 strains were isolated from four patients with AIDS or AIDS-related complex (ARC) (patients 100, 101, 103, and 104) who received an alternating regimen of AZT (7 days) and ddC (7 days To isolate primary HIV-1 strains, peripheral blood mononuclear cells (PBMCs) (1-2 x 106) from each patient were cocultured with phytohemagglutinin (PHA)-activated PBMCs (PHA-PBMCs, 1-2 x 106) from HIV-1-seronegative volunteers in 24-well microtiter culture plates in 2 ml of culture medium [RPMI 1640 medium/15% heat-inactivated fetal calf serum/recombinant interleukin 2 at 10 units per ml (Amgen Biologicals)/4 mM L-glutamine/penicillin at 50 units per ml/streptomycin at 50 ug/ml]. When the level of p24 Gag protein in the culture supernatant reached .10 ng/ml as assessed by RIA (Dupont), the supernatant was collected as a source of infectious virions.
Determination of Sensitivity of Clinical HIV-1 Strains Agant Drus. In the current study, each pair of pre-and posttherapy isolates to be compared was simultaneously titrated for infectivity and assessed for drug sensitivity. To determine changes in drug sensitivity, PHA-PBMCs were first exposed to various concentrations of drug for 2 hr, then exposed to a 20x tissue culture 50% infectious dose (TCID50) of each virus isolate. To confirm that the viral dose used was the desired one, the inoculum was retitrated for TCID50 in the same assay. The drug concentrations used were 0.0005, 0.005, 0.05, 0.5, 5, 50 ,uM for AZT; 0.005, 0.05, 0.5, 2, 5 ,uM for ddC; and 0.1, 1, 10, 50, 100 juM for ddM. The sensitivity of a given HIV-1 strain against a drug was defined as the drug concentration that yielded 50% p24 Gag protein-negative wells (CN5o) on days 8-10 in culture. When concentrations of p24 Gag protein were <0.6 ng/ml, representing the minimum Abbreviations: AZT, 3'-azido-3'-deoxythymidine; CN5o, concentration yielding 50%O negative wells; ddC, 2',3'-dideoxycytidine; ddI, 2',3'-dideoxyinosine; HIV 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. detection limit (10) , cultures were defined as negative wells. All culture assays were done in quadruplicate in 24-well microtiter culture plates. The variability in CN50 values was generally within a factor of -6 for AZT, -2 for ddC, and -2 for ddM.
Determination of Nucleotide Sequences. Cell lysates from coculture of PHA-PBMCs with patient's PBMCs were subjected to PCR as previously described by Saiki et al. (11) with minor modifications. The primers used for amplification of a 1.7-kb segment ofthepol gene were 5'-TTGCACTTTGAAT-TCTCCCATTAG-3' and 5'-CTTATCTATTCCATCTA-GAAATAGT-3', as described by Larder and Kemp (2) . After PCR, the pol fragment amplified was digested with EcoRI and Xba I and inserted into the pTZ19R vector. Competent Escherichia coli (strain DH5a) were then transformed with the pol-inserted pTZ19R, which was subsequently purified and sequenced by the dideoxynucleotide chain-termination method. 
RESULTS
In Vitro Drug Sensitivity of HIV- Five patients who received ddI were also examined. Three of five patients had received AZT before ddI therapy and showed a high level of insensitivity to AZT at entry ( Fig phenotypic changes truly represents reduced sensitivity to ddC is unclear. However, no detectable difference in the sensitivity to ddI between pre-and posttherapy HIV-1 strains isolated from any of the five patients was detected (Fig. 2C) HIV-1 strain isolated from a patient receiving ddC therapy.
In our study, however, the Asp-69-carrying HIV-11olpog, showed no detectable decrease in sensitivity to ddC (Fig.  1B) , and three other HIV-1 strains isolated from patients receiving AZT/ddC did not have this substitution (Fig. 3 ). An AZT-Insensitive HIV-1 Strain That Has None of the Previously Reported AZT-Related Amino Acid Mutations.
HIV-1lO3post4lmo showed a substantial decrease in sensitivity to ddC (40-fold increase in CN50) and a relative insensitivity to ddI (4.5-fold increase in CN50) in addition to a high level of AZT insensitivity (200-fold increase in CN50 (Fig. 4) (Fig. 2A at time 0) . Interestingly, these strains resumed relative sensitivity to AZT after switching to ddM. HIV-12o4pre had the Lys-70
Arg(3/4) substitution that should be related to the prior AZT therapy; however, after 18 mo of ddI therapy followed by 3 mo of AZT therapy, this patient's posttherapy strain lost the Lys-70 -* Arg substitution, reverting to the wild-type amino acid Lys-70, while it acquired the Thr-215 -* Tyr substitution that is thought to correlate with insensitivity to AZT (2) . In fact, the CN50 of HIV-1204pot (16 1.M) was still relatively high, indicating that HIV-12wpost was yet substantially insensitive to AZT (Fig. 2A) ERS200pr. (Table 1) .
DISCUSSION
In this study, three of four post-AZT/ddC strains showed no significant decrease in sensitivity to ddC, although all strains had developed high levels of AZT insensitivity. In a separate pediatric study, we have isolated an additional seven pairs of pre-and post-AZT/ddC strains and have seen the development ofa high level ofAZT insensitivity in four such patients, despite the addition of ddC to the therapy (R.N.H., T.S., P. A. Pizzo, and H.M., unpublished observations). These results suggest that although the alternating regimen of AZT and ddC may reduce the side effects of each drug and conceivably have clinical advantages over monotherapy, the combined AZT/ddC therapy does not prevent the development of HIV-1 variants less susceptible to AZT.
One AZT/ddC-insensitive strain, HIV-11o3post41mo, had no previously reported AZT-related mutations, but seven distinctive amino acid substitutions were found in this strain. These results suggest either that the amino acid substitutions in HIV-1l13post41mo provided a replicative advantage in the presence of AZT that exceeded that provided by combinations of the previously reported AZT-related substitutions or that the mutations observed in HIV-1lO3post-lmo caused conformational changes incompatible with the previously reported AZT-related substitutions. The most remarkable substitution identified in HIV-11o3pst is the substitution for glutamine at position 151 with methionine [Gln-151 -* Met (8/ 8) ]. This residue is part of a highly conserved amino acid sequence (Leu-Pro-Gln-Gly, amino acids 149-152 in Fig. 3 ), termed motif B, which is seen in each of 26 different retroviruses (13, 14) including HIV-1, HIV-2, simian immunodeficiency virus, human T-cell leukemia virus, and a number of animal retroviruses. Most recent x-ray crystallography of the HIV-1 RT has suggested that Gln-151 lies in (or adjacent to) the 3-strand 8, which is located close to the putative polymerase active site (15) . Thus, the Gln-151 Met substitution could alter the interaction between the RT and dNTP or change the interaction between the enzyme and the template. In the current study, no appreciable decrease in sensitivity to ddI was detected in five different post-ddl HIV-1 strains, although the decreased sensitivity could have been so modest in degree that the difference was not readily detected. St. Clair and coworkers (9) have reported that HIV-1 strains isolated after ddI therapy developed decreased sensitivity (up to 26-fold) to ddI as compared with pretherapy isolates. It is possible that their use of RT activity and different PBMC batches rather than the use of biologically more stable p24 Gag protein and a single PBMC batch for comparison could have resulted in greater variability.
The acquisition of the Leu-74 --Val substitution in addition to the Thr-215 -* Tyr substitution appears to provide HIV-1 with a replication advantage in the presence of ddI; however, in the absence of ddI, the Leu-74 --Val substitution may cause a significant replication disadvantage. This result may explain why HIV-1 mutants with the Leu-74 -+ Val substitution were rapidly eliminated from the virus population when therapy no longer included ddI (Table 1) , although elucidation of the conformational and functional basis for the decreased susceptibility to AZT and the Leu-74 -* Val substitution-related restoration of AZT sensitivity will depend on continued analysis of RT by x-ray crystallography and related technologies (15, 16) .
HIV-1 apparently undergoes selection pressure to develop reduced susceptibility to AZT. RT of AZT-insensitive variants could, in theory, discriminate between AZT triphosphate and dTTP by the presence or absence ofthe tubular and bulky 3'-azido group (17) . In this regard, the close structural resemblance of ddATP and ddCTP (the putative active moieties of ddI and ddC, respectively) to their natural corresponding nucleotides (dATP and dCTP, respectively) may make it more difficult for the virus to mutate to efficiently exclude ddATP or ddCTP, while preserving the function of RT. Indeed, molar-refraction data (18) indicate that an azido group is about three times larger than a hydroxyl group, whereas a hydrogen molecule is 2-fold smaller than a hydroxyl group. It is possible that the mutations affect the template-binding site in RT and change the ability of the enzyme to discriminate between natural dNTP and ddNTP, as proposed by Kohlstaedt et al. (15) . However, the relationship between the structural resemblance of the nucleotides and development of drug resistance is as yet highly hypothetical and requires future assessment.
